Cordlife Group Limited Receives Regulatory Action Notice from Singapore MOH

Date: 1 December 2025
Company: Cordlife Group Limited
Event: Receipt of Notice of Regulatory Action, Significant Operational Restrictions Imposed

Key Points from the Report

• Regulatory Restrictions: The Ministry of Health (MOH) has imposed strict new conditions on Cordlife’s cord blood banking service licence (CBBS Licence) effective from 26 November 2025. The company is prohibited from collecting, testing, processing, or storing new cord blood units (CBUs) for the remainder of its licence period, except under tightly defined circumstances.
• Permitted Activities: Cordlife may only:
  • Store existing CBUs
  • Facilitate transfer of existing CBUs to local or accredited overseas CBBS providers upon written client request
  • Facilitate retrieval of existing CBUs for clinical purposes (transplant)
  • Dispose of CBUs, if instructed or authorised in writing by clients

  All transfers, retrievals, and disposals are subject to strict documentation and must respect client instructions.

• Governance and Quality Control: Cordlife is required to:
  • Replace its Clinical Governance Officer with a suitably qualified individual, as per Healthcare Services (Cord Blood Banking Service) Regulations 2021, employed full-time
  • Release stored CBUs for clinical use only after review by a qualified haematologist
  • Retrospectively review all CBUs stored since 14 January 2025, investigate non-conformances, and implement remedial actions
  • Disclose any non-conformances to the infant’s mother, who must be counselled by a haematologist, and allow the mother to decide on the disposition of the CBU
  • Review all laboratory activities since 14 January 2025 for non-conformance and implement corrective/preventive measures
  • Re-train all laboratory personnel and implement effective supervisory and documentation frameworks
• Long-Term Impact: These conditions will remain in force even if Cordlife’s CBBS licence is renewed in January 2026 and will only be lifted when the company demonstrates a consistent ability to meet all regulatory requirements.
• Immediate Operational Changes: Cordlife voluntarily stopped the collection, testing, processing, and storage of any new CBUs as of 30 September 2025.
• Financial Uncertainty: The company faces significant uncertainty regarding its financial performance for the year ending 31 December 2025, especially pending the outcome of investigations into the Remaining 3 cryogenic storage tanks, whose risk status due to potential temperature excursions remains unclear.
• Going Concern Risk: The Board has previously published a detailed assessment of the company’s ability to continue as a going concern, factoring in multiple risk scenarios. Investors are urged to review this assessment, given the heightened uncertainties.

Important Considerations for Shareholders

• Share Price Sensitivity: The regulatory action, which halts new revenue-generating activities, creates a high degree of uncertainty about Cordlife’s future earnings and operational viability. This is a material development that may significantly affect the company’s share price.
• Potential for Further Regulatory Action: The MOH conditions could be extended beyond January 2026 if Cordlife does not meet regulatory standards, raising risks of continued operational restrictions.
• Uncertainty About Financial Impact: The unresolved issues with the three cryogenic storage tanks and the inability to assess their risk status mean that potential liabilities or losses may arise, impacting future financial results.
• Going Concern Risks: The company’s ability to operate as a going concern is under review, and any negative developments could result in further share price declines or operational disruptions.

Investor Actions and Outlook

Cordlife Group Limited is currently reviewing its response to the MOH notice with its professional advisers and technical team. The company has committed to providing further updates as material developments arise, especially if there are changes to its ability to continue as a going concern.

Investors should exercise caution in trading Cordlife shares until more clarity emerges on the company’s operational and financial outlook.

Disclaimer

This article contains forward-looking statements and is based on information currently available. Actual outcomes may differ materially due to risks, regulatory uncertainties, and operational developments. Investors should consult their professional advisers before making investment decisions and monitor for further company updates.

View Cordlife Historical chart here